A phase i and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 1, 2009, Pages 33-40

  Muindi, Josephia R ^a   Johnson, Candace S ^a   Trump, Donald L ^a   Christy, Renee ^a   Engler, Kristie L ^a   Fakih, Marwan G ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Calcitriol; Dexamethasone; Pharmacokinetics; Tolerability

Indexed keywords

CALCITRIOL; DEXAMETHASONE; GEFITINIB; LOPERAMIDE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SARCOMA; SOLID TUMOR; STOMACH CANCER; TREATMENT OUTCOME; VASCULITIS;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CALCITRIOL; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERCALCEMIA; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; QUINAZOLINES;

EID: 70349627040     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1000-2     Document Type: Article

References (27)

1. H Tsuchiya H Morishita K Tomita Y Ueda M Tanaka 1993 Differentiating and antitumor activities of 1α, 25-dihydroxyvitamin D3 in vitro and 1 α-hydroxyvitamin D3 in vivo on human osteosarcoma J Orthop Res 11 122 130 8423514 10.1002/jor.1100110114 1:CAS:528:DyaK3sXktVWmu7c%3D
2. U Testa R Masciulli E Tritarelli R Pustorino G Mariani R Martucci T Barberi A Camagna M Valtieri C Peschle 1993 Transforming growth factor- potentiates vitamin D3-induced terminal monocytic differentiation of human leukemic cell lines J Immunol 150 2418 2430 8383719 1:CAS:528:DyaK3sXktVWltL8%3D
3. JA Eisman DH Barkla PJ Tutton 1987 Suppression of in vivo growth of human cancer solid tumor xenografts by 1, 25-dihydroxyvitamin D3 Cancer Res 47 21 25 3024816 1:CAS:528:DyaL2sXps1yktg%3D%3D
4. I Chung MK Wong G Flynn WD Yu CS Johnson DL Trump 2006 Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells Cancer Res 66 8565 8573 16951169 10.1158/0008-5472.CAN-06-0905 1:CAS:528:DC%2BD28XovF2itL4%3D (Pubitemid 44449170)
5. PA Hershberger RA Modzelewski ZR Shurin RM Rueger DL Trump CS Johnson 1999 1, 25-dihydroxycholecalciferal (1, 25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21 (waf1/Cip1) in vitro and in vivo Cancer Res 59 2644 2649 10363987 1:CAS:528:DyaK1MXjs1ymtrw%3D
6. RJ Bernardi DL Trump WD Yu TF McGuire PA Hershberger CS Johnson 2001 Combination of 1α, 25-dihydroxyvitamin D3 with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling Clin Cancer Res 7 4164 4173 11751517 1:CAS:528:DC%2BD38XltFShug%3D%3D
7. PA Hershberger TF McGuire WD Yu EG Zuhowski JH Schellens MJ Egorin, et al. 2002 Cisplatin potentiates 1, 25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression Mol Cancer Ther 10 821 829
8. X Wang GP Studzinski 2001 Activation of extracellular signal-regulated kinases (ERKs) defines the first phase of 1, 25-dihydroxyvitamin D3-induced differentiation of HL60 cells J Cell Biochem 80 471 482 11169731 10.1002/1097-4644(20010315)80:4<471::AID-JCB1001>3.0.CO;2-J 1:STN:280:DC%2BD3M3isV2htg%3D%3D (Pubitemid 32127462)
9. WM Tong E Kállay H Hofer W Hulla T Manhardt M Peterlik HS Cross 1998 Growth regulation of human colon cancer cells by epidermal growth factor and 1, 25-dihydroxyvitamin D3 is mediated by mutual modulation of receptor expression Eur J Cancer 34 2119 2125 10070321 10.1016/S0959-8049(98)00267-6 1:CAS:528:DyaK1MXitVWnsg%3D%3D (Pubitemid 28546952)
10. R Bernardi C Johnson D Trump 2002 ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGDR-TKI), enhances the antiproliferative effects of calcitriol (1, 25-dihydroxyvitamin D3) in squamous cell carcinoma: effects on ERK and Akt [abstract 3883] Proc Am Assoc Cancer Res 43 783
11. MG Fakih DL Trump JR Muindi JD Black RJ Bernardi PJ Creaven J Schwartz MG Brattain A Hutson R French CS Johnson 2007 A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors Clin Cancer Res 13 1216 1223 17317832 10.1158/1078-0432.CCR-06-1165 1:CAS:528:DC%2BD2sXhvF2hsbg%3D (Pubitemid 46424063)
12. TG Davidson 2001 Conventional treatment of hypercalcemia of malignancy Am J Health Syst Pharm 58 Suppl 3 S8 S15 11757206
13. M Jibani NH Hodges 1985 Prolonged hypercalcemia after exposure to vitamin D3 Br Med J 290 748 749 10.1136/bmj.290.6470.748 1:STN:280:DyaL2M7itlKquw%3D%3D
14. RG Klein SB Arnaud JC Gallagher HF Deluca BL Riggs 1977 Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose J Clin Invest 60 253 259 874087 10.1172/JCI108762 1:CAS:528:DyaE2sXkvFKltL4%3D
15. Y Suzuki Y Ichikawa E Saito M Homma 1983 Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy Metabolism 32 151 156 6298567 10.1016/0026-0495(83)90221-4 1:STN:280:DyaL3s7ktV2qsw%3D%3D (Pubitemid 13194649)
16. WD Yu MC McElwain RA Modzelewski DM Russell DC Smith DL Trump CS Johnson 1998 Enhancement of 1, 25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone J Natl Cancer Inst 90 134 141 9450573 10.1093/jnci/90.2.134 1:CAS:528:DyaK1cXosleltA%3D%3D
17. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
18. DC Smith CS Johnson CC Freeman J Muindi JW Wilson DL Trump 1999 A phase I trial of calcitriol (1, 25-dihydroxycholecalciferol) in patients with advanced malignancy Clin Cancer Res 5 1339 1345 10389917 1:CAS:528:DyaK1MXkt1Oqurk%3D
19. KF Kane MJ Langman GR Williams 1996 Antiproliferative responses to two human colon cancer cell lines to vitamin D3 are differently modified by 9-cis-retinoic acid Cancer Res 56 623 632 8564982 1:CAS:528:DyaK28XnslOhtw%3D%3D
20. J Akhter M Goerdel DL Morris 1996 Vitamin D3 analogue (EB 1089) inhibits in vitro cellular proliferation of human colon cancer cells Br J Surg 83 229 230 8689173 10.1002/bjs.1800830225 1:STN:280:DyaK283ks12ktw%3D%3D (Pubitemid 26050150)
21. JR Muindi Y Peng DM Potter PA Hershberger JS Tauch MJ Capozzoli, et al. 2002 Pharmacokinetics of high dose calcitriol: results obtained during a phase one trial of calcitriol and paclitaxel Cancer Pharmacol Ther 72 648 659 10.1067/mcp.2002.129305 1:CAS:528:DC%2BD3sXltF2qtQ%3D%3D (Pubitemid 36021004)
22. TM Beer M Munar WD Henner 2001 A phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation Cancer 91 2431 2439 11413535 10.1002/1097-0142(20010615)91: 12<2431::AID-CNCR1278>3.0.CO;2-3 1:CAS:528:DC%2BD3MXltVOnsb4%3D (Pubitemid 32552832)
23. TM Beer M Javle GN Lam WD Henner A Wong DL Trump 2005 Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer Clin Cancer Res 11 7794 7799 16278401 10.1158/1078-0432. CCR-05-0552 1:CAS:528:DC%2BD2MXhtF2isL7E (Pubitemid 41611623)
24. TM Beer MM Javle CW Ryan M Garzotto GN Lam A Wong WD Henner CS Johnson DL Trump 2007 Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer Cancer Chemother Pharmacol 59 581 587 17066293 10.1007/s00280-006-0299-1 1:CAS:528:DC%2BD2sXhvVeiur0%3D (Pubitemid 46295122)
25. JR Muindi RA Modzelewski Y Peng DL Trump CS Johnson 2004 Pharmacokinetics of 1α, 25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses Oncology 66 62 66 15031600 10.1159/000076336 1:CAS:528:DC%2BD2cXitlyitLc%3D (Pubitemid 38410681)
26. Y Ma WD Yu PA Hershberger G Flynn RX Kong DL Trump CS Johnson 2008 1alpha, 25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model Mol Cancer Ther 7 3047 3055 18790784 10.1158/1535-7163.MCT-08-0243 1:CAS:528:DC%2BD1cXhtFSmsL%2FN
27. PA Hershberger WD Yu RA Modzelewski RM Rueger CS Johnson DL Trump 2001 Calcitriol (1, 25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis Clin Cancer Res 7 1043 1051 11309356 1:CAS:528:DC%2BD3MXjs1elt7Y%3D